Max Healthcare Institute Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of Rs. 1.5 per equity share.
MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Max Healthcare reported consolidated revenue from operations of Rs. 7,028.5 crore for FY25, up ~30% from Rs. 5,406 crore in FY24, driven mainly by the acquisition of Jaypee Healthcare in Oct–Nov 2024. Profit after tax rose modestly to Rs. 1,075.9 crore vs Rs. 1,057.6 crore (up ~1.7%), with an exceptional item of Rs. 73.6 crore linked to the Jaypee acquisition. Q4 FY25 revenue was Rs. 1,909.7 crore and PAT was Rs. 319 crore, up sharply from Rs. 251.5 crore in Q4 FY24. The Board recommended a final dividend of Rs. 1.5 per share (15% of face value), subject to shareholder approval. The company also approved adding ~100 beds at Max Super Speciality Hospital, Nagpur (existing 186 beds) and ~120 beds at Vaishali via a Rs. 120 crore land buy. Deloitte's term as statutory auditor ends at the 24th AGM; S.R. Batliboi & Co. LLP has been appointed for 5 years (FY26–FY30).
Strong top-line growth from acquisitions and expansion, but modest bottom-line growth and a dip in EBITDA margin suggest margin pressure in the near term. The dividend signals confidence, while the ongoing bed additions and Jaypee integration should support future revenue, though investors should watch margin trends and integration costs.